Es posible esterilizar las máscaras N95 y los barbijos quirúrgicos

Thrombosis and Thromboembolism Associated with COVID-19

Coronavirus disease 2019 (COVID-19) is a viral respiratory illness that can cause a severe acute respiratory syndrome (SARS-CoV-2), predisposing patients to thrombosis (both in veins and arteries) due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for different indications may now become infected with COVID-19, which can<a href="https://solaci.org/en/2020/05/13/thrombosis-and-thromboembolism-associated-with-covid-19/" title="Read more" >...</a>

The most read scientific articles in april

The most read scientific articles on interventional cardiology in april

01- ECS Guidelines for COVID-19 Management One of the first statements in this document points out these are not “regular guidelines” developed after thorough analysis of all the available evidence published since the last update. Instead, they are meant to provide temporary basic management pointers on how to handle different scenarios of cardiac patients in the<a href="https://solaci.org/en/2020/05/06/the-most-read-scientific-articles-on-interventional-cardiology-in-april/" title="Read more" >...</a>

Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) regardless initial indications. All evidence in support of these arguments might be failing to show the risk of non-culprit lesion events in patients with acute coronary syndromes (ACS). Potent and prolonged antithrombotic therapies<a href="https://solaci.org/en/2020/04/22/are-non-culprit-lesions-really-innocent/" title="Read more" >...</a>

Reperfusion in the Time of COVID-19. What Has Changed?

We are living a pandemic due to the new COVID-19, but the world was already in the midst of a pandemic of cardiovascular disease. Both challenges defy healthcare systems worldwide, and the worst part is that they can coexist. Some symptoms for both diseases can overlap (such as respiratory distress) and they are unreliable, like<a href="https://solaci.org/en/2020/04/17/reperfusion-in-the-time-of-covid-19-what-has-changed/" title="Read more" >...</a>

AHA 2019 | COMPLETE: la revascularización completa es superior por tratar otras placas vulnerables

AHA 2019 | COMPLETE: Complete Revascularization Is Superior since It Treats Other Vulnerable Plaque

This COMPLETE sub-study using optical coherence tomography (OCT) showed the prevalence of vulnerable lesions other than the culprit which should provide a physiopathological explanation of the benefit of complete revascularization observed in the original study.  STEMI patients with multivessel disease will benefit from complete revascularization in terms of reduced cardiovascular death and repeat MI according<a href="https://solaci.org/en/2019/11/27/aha-2019-complete-complete-revascularization-is-superior-since-it-treats-other-vulnerable-plaque/" title="Read more" >...</a>

TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Courtesy of Dr. Carlos Fava. Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3 years. However, beyond such term, we had no valid information. Researchers analyzed the 5-year follow-up results for the<a href="https://solaci.org/en/2019/10/01/tct-2019-excel-left-main-coronary-artery-angioplasty-with-favorable-results-at-5-years/" title="Read more" >...</a>

Oportunidades perdidas en pacientes con enfermedad vascular periférica

Though Systolic BP Seems More Important, Diastolic BP Should Not Be Disregarded

Systolic hypertension is more often associated to cardiovascular events. However, diastolic blood pressure should not be disregarded, since it can also predict even worse outcomes. Although systolic blood pressure is very frequently associated to adverse cardiovascular events, by no means should diastolic blood pressure be considered unimportant. Such is the message of this study recently<a href="https://solaci.org/en/2019/07/25/though-systolic-bp-seems-more-important-diastolic-bp-should-not-be-disregarded/" title="Read more" >...</a>

ACC 2019 | Prometedores resultados para el TAVI en bajo riesgo

ACC 2019 | TAVR in Low-Risk Patients Is Noninferior

Courtesy of Dr. Carlos Fava. Self-expanding supraannular aortic valves have proved to be superior to surgery in high-risk patients and noninferior in intermediate-risk patients. However, the current challenge is posed by low-risk, generally younger, patients. In that sense, our purpose is to determine device effectiveness and safety in terms of mortality and stroke rates (which are<a href="https://solaci.org/en/2019/03/19/acc-2019-tavr-in-low-risk-patients-is-noninferior/" title="Read more" >...</a>

Abluminal Sirolimus and luminal CD34 antibody layer: Is COMBO the Future of Stents?

This large cohort of patients treated with the dual therapy COMBO stent has showed excellent outcomes after one year (MASCOT Post Marketing Registry). Long term follow up is still ongoing. The COMBO stent is a new device with an abluminal sirolimus biodegradable polymer and a luminal layer of antibodies that promotes endothelial healing (anti CD34+)<a href="https://solaci.org/en/2019/03/11/abluminal-sirolimus-and-luminal-cd34-antibody-layer-is-combo-the-future-of-stents/" title="Read more" >...</a>

The 10 Most Read Articles of January

1- These Were the Most Relevant Article of 2018 in the Field of Coronary Diseases Read the best articles on coronary heart disease from 2018 at solaci website. Read more   2- The 10 Commandments of ESC’s New STEMI Guidelines The authors have given an entertaining account of the most relevant points and differences between<a href="https://solaci.org/en/2019/02/15/the-10-most-read-articles-of-january/" title="Read more" >...</a>

acute myocardial infarction